Search clinical trials for: QL1012

Total 99 results

Qilu Pharmaceutical Co., Ltd.

Completed

Efficacy and Safety of QL1012 in Women for Assisted Reproductive Treatment

Infertility

China
Smilebiotek Zhuhai Limited

Active, not recruiting

QA102 Phase II Study in Subjects With Dry AMD (AMEND)

Dry Age-related Macular Degeneration

United States
Guangdong Ruishun Biotech Co., Ltd
Anhui Provincial Hospital

Recruiting

RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT

Acute Myeloid Leukemia

China
Ayala Pharmaceuticals, Inc,

Active, not recruiting

A Study of AL102 in Patients With Progressing Desmoid Tumors (RINGSIDE)

Desmoid Tumor | Desmoid

United States, Spain, United Kingdom, Australia, Korea, Republic of, Israel, Belgium, Germany, Netherlands, Italy, Poland
Ayala Pharmaceuticals, Inc,

Terminated

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY)

Triple Negative Breast Cancer

United States, Belgium, Israel, Spain, United Kingdom
Ayala Pharmaceuticals, Inc,

Completed

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY)

Adenoid Cystic Carcinoma

United States, Canada, France, United Kingdom, Israel, Netherlands
Smilebiotek Zhuhai Limited

Completed

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

Age-related Macular Degeneration

United States
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Completed

A First-in-Human Study of QY101 Ointment in Adult Subjects

Healthy Volunteer

China
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Recruiting

A Study of QY101 Ointment in Subjects With Plaque Psoriasis

Psoriasis

China
Qilu Pharmaceutical Co., Ltd.

Recruiting

A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis

Lupus Nephritis

China
Guangdong Ruishun Biotech Co., Ltd
First Affiliated Hospital of Zhejiang University

Recruiting

Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML

Acute Myeloid Leukemia

China
M.D. Anderson Cancer Center

Recruiting

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Adenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma

United States
Amckaus PTY LTD.
Novotech (Australia) Pty Limited

Recruiting

QG101-23-0 Capsules SAD and MAD Study in Healthy Subjects

Healthy Volunteers

Australia
Glia, LLC

Completed

Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101

Ocular Surface Disease

United States
Alector Inc.

Completed

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

Healthy

United States
Rocket Pharmaceuticals Inc.

Active, not recruiting

Gene Therapy for Fanconi Anemia, Complementation Group A

Fanconi Anemia Complementation Group A

United States
Rocket Pharmaceuticals Inc.

Active, not recruiting

Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A

Fanconi Anemia Complementation Group A

Spain
Rocket Pharmaceuticals Inc.

Unknown

A Clinical Trial to Evaluate the Safety of RP-L102 in Pediatric Subjects With Fanconi Anemia Subtype A

Fanconi Anemia Complementation Group A

United States
Takeda

Completed

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

Parkinson's Disease

Japan
Certmedica International GmbH

Completed

Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate Obese and Overweight Subjects (POSO)

Weight Loss

Italy
Autotelicbio

Recruiting

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

Diabetes Mellitus, Type 2 | Essential Hypertension

Korea, Republic of
Yongpeng Wang

Recruiting

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Ovarian Cancer

China
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Takeda

Completed

A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants

Parkinson's Disease

Japan
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers

Healthy Volunteer

Germany
Certmedica International GmbH
University Hospital, Bonn

Completed

Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption

Cholesterol Lowering

Germany
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers

Healthy Volunteer

Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

Hypercholesterolemia

Germany
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Dose-escalating Safety Study in Subjects on Stable Statin Therapy

Hypercholesterolemia

Netherlands, United States
Parke-Davis

Completed

A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients

HIV Infections

United States
Parke-Davis

Completed

A Study of CI-1012 in HIV-Infected Patients

HIV Infections

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease (RADICHOL II)

Coronary Artery Disease | Heterozygous Familial Hypercholesterolemia

United States, Canada
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Canada, Brazil, Taiwan, Singapore, South Africa, United Kingdom
Takeda

Completed

A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

Parkinson's Disease

Japan
Takeda

Completed

A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients

Parkinson's Disease

Japan
Qilu Pharmaceutical Co., Ltd.

Not yet recruiting

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Tumor

China
Second Affiliated Hospital, School of Medicine,...
Shanghai Junshi Bioscience Co., Ltd.; Qilu Pharmaceutical Co., Ltd.

Unknown

QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer (BEVTOR)

MSS | pMMR | Refractory Metastatic Colorectal Cancer

China
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia (RADICHOL 1)

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States, Taiwan, Brazil, Canada, South Africa, United Kingdom, Singapore
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

Hypercholesterolemia, Familial

United States, Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients

Hypercholesterolemia | Coronary Heart Disease

United States
Azienda di Servizi alla Persona di Pavia

Completed

Polyglucosamine L112 in Overweight and Obese Subjects

Obesity

Italy
Kastle Therapeutics, LLC

Completed

A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol (FOCUS FH)

Hypercholesterolemia | Heterozygous Familial

United States, Italy, Poland, Ukraine, United Kingdom, Germany, Hong Kong, Taiwan, Spain, Argentina, Belgium, Israel, Malaysia, South Africa, Turkey, Netherlands, Korea, Republic of, Canada, New Zealand, Russian Federation, Brazil, Austral... and more
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Hypercholesterolemia | Coronary Heart Disease

South Africa, Germany, United States, United Kingdom, Canada, Czech Republic
Qilu Pharmaceutical Co., Ltd.

Completed

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

Breast Cancer

China
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects (ASSIST)

Metabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Metabolic Disorder

Netherlands
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditions

United States
Kastle Therapeutics, LLC
Ionis Pharmaceuticals, Inc.

Completed

Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration

Metabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Lipid Metabolism, Inborn Errors | Hypobetalipoproteinemias | Hypolipoproteinemias | Hypolipopro... and other conditions

Netherlands
Mucosal Therapeutics

Completed

Efficacy of SNX-1012 in the Treatment of Oral Mucositis

Stomatitis | Oral Mucositis

United States, India
Autotelicbio

Completed

Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012

Healthy Adult Volunteers

Korea, Republic of
Exelixis

Terminated

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States

Search clinical trials for: QL1012

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations